The Sage Group Announces $100M+ Transaction between medac GmbH and Medexus Pharma for Treosulfan in

The Sage Group Inc. served as exclusive advisor to medac GmbH on this $100M+ transaction.

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States



Sage Transaction Announcement Medac Mexe
.
Download • 252KB

TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“Medexus Pharma” and together with Medexus, the “Company”) entered into a Commercialization and Supply Agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. (“medac”), pursuant to which medac has granted Medexus Pharma an exclusive license to commercialize treosulfan, a bifunctional alkylating agent, in the United States (the “License Agreement”).


Treosulfan is an innovative, orphan-designated agent developed for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (“allo-HSCT”). If approved by the U.S. Food and Drug Administration (“FDA”), the Company expects that a treosulfan-based regimen will be the first in a new conditioning treatment class, Reduced Toxicity Conditioning, resulting in a unique combination of improved survival outcomes compared to reduced-intensity regimens and decreased toxicity compared to standard myeloablative regimens. A Prescription Drug User Free Act (“PDUFA”) date to review the New Drug Application (“NDA”) in respect of treosulfan by the FDA has been scheduled for August 2021.


The Company intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan. medac conducted a phase III randomized study (the “Phase III Study”) comparing the results of treosulfan-based therapy with busulfan-based reduced intensity conditioning in advance of allo-HSCT for adult patients with acute myeloid leukemia (“AML”) and myelodysplastic syndrome (“MDS”) who were considered ineligible for standard myeloablative conditioning regimens. The planned confirmatory interim analysis of the Phase III Study demonstrated that non-inferiority was achieved in the treosulfan group compared to the busulfan group in two-year event-free survival. *FDA granted medac Orphan Drug Designation for Treosulfan for conditioning treatment prior to allo-HSCT in malignant and non-malignant disease in adults and pediatric patients. FDA approval is anticipated in 2021 For additional information about this transaction, please contact:

Wayne Pambianchi +1-908-2306170 wpambianchi@sagehealthcare.com

Dr. Bill Mason +44 (0)7785 950134 wtm@sagehealthcare.com

About Us

The Sage Group, Inc. (“Sage”) is a global leader in providing strategic and transactional advice to companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and has active alliances with companies similar to Sage in China, Japan, and India. Since its founding in 1994, The Sage Group has advised more than 300 clients from around the world and completed transactions which include licenses, partnerships/alliances, mergers/acquisitions and divestitures with values ranging from $5 million to $500 million.


Sage is comprised of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.

The range of services offered includes:

  • Strategic alliances and licensing/partnering

  • M&A, divestment, buy- and sell- side

  • Global product and technology acquisition searches

  • Strategic assessment and planning

  • Due diligence, technology and molecule assessment, valuation

  • New ventures, interim management

Sage’s Executive Directors have been Founders, Chairmen, Presidents, CEOs and COOs of a number of emerging health care companies and have also held senior level management positions in large multi-national organizations.

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Social Icon